交易 Kymera Therapeutics, Inc. - KYMR CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.18 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.030779% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | -0.013666% | ||||||||
隔夜费时间 | 22:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Feb 2, 2023 | 38.69 | 1.64 | 4.43% | 37.05 | 39.72 | 35.90 |
Feb 1, 2023 | 36.58 | 0.61 | 1.70% | 35.97 | 37.57 | 35.49 |
Jan 31, 2023 | 37.34 | 1.96 | 5.54% | 35.38 | 37.91 | 35.33 |
Jan 30, 2023 | 36.32 | 0.35 | 0.97% | 35.97 | 36.49 | 35.39 |
Jan 27, 2023 | 36.81 | 2.20 | 6.36% | 34.61 | 37.51 | 34.61 |
Jan 26, 2023 | 35.42 | -0.54 | -1.50% | 35.96 | 37.38 | 34.85 |
Jan 25, 2023 | 36.65 | 0.96 | 2.69% | 35.69 | 37.10 | 35.54 |
Jan 24, 2023 | 37.22 | 2.65 | 7.67% | 34.57 | 37.26 | 34.57 |
Jan 23, 2023 | 35.51 | 0.65 | 1.86% | 34.86 | 35.54 | 33.96 |
Jan 20, 2023 | 34.92 | 1.51 | 4.52% | 33.41 | 35.05 | 32.97 |
Jan 19, 2023 | 33.13 | -0.34 | -1.02% | 33.47 | 34.06 | 31.52 |
Jan 18, 2023 | 34.53 | 0.80 | 2.37% | 33.73 | 35.48 | 33.73 |
Jan 17, 2023 | 34.61 | -0.16 | -0.46% | 34.77 | 34.87 | 33.61 |
Jan 13, 2023 | 34.48 | 2.39 | 7.45% | 32.09 | 34.93 | 32.08 |
Jan 12, 2023 | 33.51 | 4.42 | 15.19% | 29.09 | 33.61 | 29.09 |
Jan 11, 2023 | 29.83 | 1.52 | 5.37% | 28.31 | 29.95 | 28.05 |
Jan 10, 2023 | 29.45 | 2.80 | 10.51% | 26.65 | 29.79 | 26.64 |
Jan 9, 2023 | 27.00 | -0.27 | -0.99% | 27.27 | 27.62 | 25.97 |
Jan 6, 2023 | 27.27 | 0.84 | 3.18% | 26.43 | 27.70 | 25.65 |
Jan 5, 2023 | 26.15 | 0.58 | 2.27% | 25.57 | 26.52 | 24.46 |
Kymera Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- 年度
- 每季度
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
总收入 | 0 | 2.934 | 34.034 | 72.832 |
收入 | 0 | 2.934 | 34.034 | 72.832 |
总营业费用 | 21.451 | 45.139 | 80.338 | 173.362 |
销售/一般/行政费用,总计 | 3.772 | 7.981 | 18.233 | 36.345 |
研究与开发 | 17.679 | 37.158 | 62.105 | 137.017 |
营业收入 | -21.451 | -42.205 | -46.304 | -100.53 |
利息收入(费用),非经营净值 | -0.016 | 0.959 | 0.711 | 0.313 |
税前净收入 | -21.467 | -41.246 | -45.593 | -100.217 |
税后净收入 | -21.467 | -41.246 | -45.593 | -100.217 |
未计算非常项目前的净收益 | -21.467 | -41.246 | -45.593 | -100.217 |
净收入 | -21.467 | -41.246 | -45.593 | -100.217 |
普通股股东可获收益 (不含非经常性项目) | -21.467 | -41.246 | -54.643 | -100.217 |
普通股股东可获收益 (含非經常性項目) | -21.467 | -41.246 | -54.643 | -100.217 |
摊薄净收入 | -21.467 | -41.246 | -54.643 | -100.217 |
摊薄后加权平均股 | 43.1386 | 43.1386 | 44.4822 | 47.989 |
扣除特别项目的每股摊薄盈利 | -0.49763 | -0.95613 | -1.22842 | -2.08833 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.49763 | -0.95613 | -1.22842 | -2.08833 |
Total Adjustments to Net Income | -9.05 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
总收入 | 18.702 | 18.519 | 20.336 | 15.275 | 9.622 |
收入 | 18.702 | 18.519 | 20.336 | 15.275 | 9.622 |
总营业费用 | 31.871 | 43.249 | 48.973 | 49.269 | 46.555 |
销售/一般/行政费用,总计 | 5.909 | 8.029 | 10.667 | 11.74 | 10.611 |
研究与开发 | 25.962 | 35.22 | 38.306 | 37.529 | 35.944 |
营业收入 | -13.169 | -24.73 | -28.637 | -33.994 | -36.933 |
利息收入(费用),非经营净值 | 0.094 | 0.07 | 0.055 | 0.094 | 0.249 |
税前净收入 | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
税后净收入 | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
未计算非常项目前的净收益 | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
净收入 | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
普通股股东可获收益 (不含非经常性项目) | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
普通股股东可获收益 (含非經常性項目) | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
摊薄净收入 | -13.075 | -24.66 | -28.582 | -33.9 | -36.684 |
摊薄后加权平均股 | 44.6496 | 45.0942 | 50.7149 | 51.4312 | 51.6511 |
扣除特别项目的每股摊薄盈利 | -0.29284 | -0.54685 | -0.56358 | -0.65913 | -0.71023 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.29284 | -0.54685 | -0.56358 | -0.65913 | -0.71023 |
- 年度
- 每季度
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
流动资产总额 | 41.79 | 92.845 | 302.339 | 451.273 |
现金和短期投资 | 41.26 | 91.957 | 296.202 | 442.418 |
现金等价物 | 41.26 | 76.015 | 31.004 | 47.976 |
短期投资 | 0 | 15.942 | 265.198 | 394.442 |
应收账款总额,净额 | 0.148 | 0 | 1.433 | 0.135 |
Prepaid Expenses | 0.382 | 0.888 | 4.704 | 8.72 |
Total Assets | 44.231 | 116.702 | 487.175 | 605.905 |
Property/Plant/Equipment, Total - Net | 2.242 | 22.083 | 20.686 | 21.307 |
Property/Plant/Equipment, Total - Gross | 2.466 | 23.132 | 22.833 | 25.223 |
Accumulated Depreciation, Total | -0.224 | -1.049 | -2.147 | -3.916 |
Other Long Term Assets, Total | 0.199 | 1.774 | 1.619 | 8.138 |
Total Current Liabilities | 4.687 | 34.57 | 110.617 | 92.542 |
Accounts Payable | 2.056 | 3.276 | 4.368 | 4.005 |
Accrued Expenses | 2.225 | 7.175 | 12.896 | 25.08 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.302 | 0.681 | 0.689 | 1.138 |
Other Current Liabilities, Total | 0.104 | 23.438 | 92.664 | 62.319 |
Total Liabilities | 5.238 | 82.028 | 203.287 | 146.267 |
Total Long Term Debt | 0.393 | 1.165 | 0.604 | 1.14 |
Capital Lease Obligations | 0.393 | 1.165 | 0.604 | 1.14 |
Other Liabilities, Total | 0.158 | 46.293 | 92.066 | 52.585 |
Total Equity | 38.993 | 34.674 | 283.888 | 459.638 |
Redeemable Preferred Stock | 73.429 | 109.08 | ||
Common Stock | 0 | 0 | 0.004 | 0.005 |
Additional Paid-In Capital | 0.774 | 2.044 | 412.777 | 689.275 |
Retained Earnings (Accumulated Deficit) | -35.21 | -76.456 | -128.765 | -228.982 |
Other Equity, Total | 0 | 0.006 | -0.128 | -0.66 |
Total Liabilities & Shareholders’ Equity | 44.231 | 116.702 | 487.175 | 605.905 |
Total Common Shares Outstanding | 43.1386 | 43.1386 | 44.4822 | 51.5362 |
Accounts Receivable - Trade, Net | 0.856 | 0.135 | ||
Long Term Investments | 162.531 | 125.187 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 340.791 | 364.806 | 543.731 | 451.273 | 431.382 |
现金和短期投资 | 333.537 | 359.107 | 536.386 | 442.418 | 420.812 |
现金等价物 | 53.098 | 84.903 | 156.819 | 47.976 | 33.733 |
短期投资 | 280.439 | 274.204 | 379.567 | 394.442 | 387.079 |
应收账款总额,净额 | 1.734 | 0.904 | 1.573 | 0.135 | 1.263 |
Accounts Receivable - Trade, Net | 0.878 | 0.904 | 1.573 | 0.135 | 1.263 |
Prepaid Expenses | 5.52 | 4.795 | 5.772 | 8.72 | 9.307 |
Total Assets | 464.552 | 434.386 | 642.453 | 605.905 | 563.06 |
Property/Plant/Equipment, Total - Net | 20.502 | 21.766 | 21.724 | 21.307 | 21.066 |
Property/Plant/Equipment, Total - Gross | 23.127 | 24.942 | 24.951 | 25.223 | 25.668 |
Accumulated Depreciation, Total | -2.625 | -3.176 | -3.227 | -3.916 | -4.602 |
Long Term Investments | 101.639 | 45.305 | 74.692 | 125.187 | 102.478 |
Other Long Term Assets, Total | 1.62 | 2.509 | 2.306 | 8.138 | 8.134 |
Total Current Liabilities | 110.137 | 108.685 | 94.493 | 92.542 | 88.339 |
Accounts Payable | 8.348 | 8.177 | 5.033 | 4.005 | 2.567 |
Accrued Expenses | 12.962 | 16.838 | 21.105 | 25.08 | 22.913 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.64 | 1.038 | 1.189 | 1.138 | 1.087 |
Other Current Liabilities, Total | 88.187 | 82.632 | 67.166 | 62.319 | 61.772 |
Total Liabilities | 189.305 | 176.282 | 159.318 | 146.267 | 134.34 |
Total Long Term Debt | 0.498 | 1.145 | 1.347 | 1.14 | 0.927 |
Capital Lease Obligations | 0.498 | 1.145 | 1.347 | 1.14 | 0.927 |
Other Liabilities, Total | 78.67 | 66.452 | 63.478 | 52.585 | 45.074 |
Total Equity | 275.247 | 258.104 | 483.135 | 459.638 | 428.72 |
Common Stock | 0.004 | 0.005 | 0.005 | 0.005 | 0.005 |
Additional Paid-In Capital | 417.096 | 424.599 | 678.358 | 689.275 | 697.597 |
Retained Earnings (Accumulated Deficit) | -141.84 | -166.5 | -195.082 | -228.982 | -265.666 |
Other Equity, Total | -0.013 | 0 | -0.146 | -0.66 | -3.216 |
Total Liabilities & Shareholders’ Equity | 464.552 | 434.386 | 642.453 | 605.905 | 563.06 |
Total Common Shares Outstanding | 44.8794 | 45.3277 | 51.2565 | 51.5362 | 51.6927 |
- 年度
- 每季度
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
净收入/起跑线 | -21.467 | -41.246 | -45.593 | -100.217 |
经营活动产生的现金 | -17.863 | 17.905 | 88.13 | -128.946 |
经营活动产生的现金 | 0.205 | 0.825 | 1.763 | 2.397 |
非现金物品 | 1.091 | 1.639 | 7.093 | 30.797 |
已付现金利息 | 0.015 | 0.046 | 0.115 | 0.158 |
营运资金的变化 | 2.308 | 56.687 | 124.867 | -61.923 |
投资活动产生的现金 | -1.356 | -16.486 | -422.588 | -99.835 |
资本支出 | -1.356 | -0.532 | -9.096 | -1.597 |
其他投资现金流量项目,总计 | 0 | -15.954 | -413.492 | -98.238 |
融资活动产生的现金 | 52.932 | 34.911 | 289.262 | 250.28 |
股票的发行(报废),净额 | 53.227 | 35.282 | 276.289 | 249.18 |
债务的发行(退还),净额 | -0.295 | -0.371 | -0.554 | -0.849 |
现金净变化 | 33.713 | 36.33 | -45.196 | 21.499 |
融资现金流项目 | 13.527 | 1.949 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.075 | -37.735 | -66.317 | -100.217 | -36.684 |
Cash From Operating Activities | -22.823 | -53.334 | -90.594 | -128.946 | -40.295 |
Cash From Operating Activities | 0.485 | 1.037 | 1.708 | 2.397 | 0.687 |
Non-Cash Items | 4.451 | 11.409 | 20.483 | 30.797 | 9.048 |
Cash Interest Paid | 0.024 | 0.054 | 0.106 | 0.158 | 0.046 |
Changes in Working Capital | -14.684 | -28.045 | -46.468 | -61.923 | -13.346 |
Cash From Investing Activities | 44.323 | 105.046 | -31.816 | -99.835 | 25.863 |
Capital Expenditures | -0.164 | -0.79 | -1.096 | -1.597 | -0.482 |
Other Investing Cash Flow Items, Total | 44.487 | 105.836 | -30.72 | -98.238 | 26.345 |
Cash From Financing Activities | 0.595 | 2.187 | 248.226 | 250.28 | 0.185 |
Financing Cash Flow Items | -0.397 | -0.397 | 1.95 | 1.949 | 0 |
Issuance (Retirement) of Stock, Net | 1.147 | 2.925 | 246.969 | 249.18 | 0.449 |
Issuance (Retirement) of Debt, Net | -0.155 | -0.341 | -0.693 | -0.849 | -0.264 |
Net Change in Cash | 22.095 | 53.899 | 125.816 | 21.499 | -14.247 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Atlas Venture | Venture Capital | 10.7654 | 5906385 | -126474 | 2023-01-12 | LOW |
BVF Partners L.P. | Hedge Fund | 8.6278 | 4733611 | 41007 | 2023-01-12 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 7.4299 | 4076383 | -1148303 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 6.216 | 3410386 | -1624554 | 2022-09-30 | LOW |
Vertex Pharmaceuticals Inc | Corporation | 5.8344 | 3201049 | 49928 | 2022-03-31 | |
Baker Bros. Advisors LP | Hedge Fund | 5.249 | 2879825 | 0 | 2022-09-30 | LOW |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 5.2431 | 2876637 | 269507 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.2046 | 2855478 | -14485 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.8946 | 2685404 | -829034 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.8611 | 2667006 | 147376 | 2022-09-30 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 3.9538 | 2169230 | 909230 | 2022-09-30 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 3.639 | 1996529 | 634040 | 2022-09-30 | HIGH |
Invus Public Equities Advisors, LLC | Investment Advisor | 2.734 | 1500000 | 500000 | 2022-09-30 | LOW |
Wasatch Global Investors Inc | Investment Advisor/Hedge Fund | 1.933 | 1060561 | 489917 | 2022-09-30 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 1.9079 | 1046743 | 270864 | 2022-09-30 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 1.451 | 796093 | 796093 | 2022-09-30 | MED |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.3139 | 720875 | -28167 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2781 | 701222 | 25375 | 2022-09-30 | LOW |
Bessemer Venture Partners | Venture Capital | 1.1226 | 615895 | 0 | 2022-09-30 | LOW |
Mainolfi (Nello) | Individual Investor | 1.0424 | 571931 | 10000 | 2022-12-08 | LOW |
为什么选择 Capital.com?让我们的数字来说话。
Capital.com Group交易計算器
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
貿易佣金
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
杠杆
20:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Kymera Therapeutics, Inc. Company profile
关于 Kymera Therapeutics Inc.
Kymera Therapeutics, Inc.是一家生物制药公司。 公司专注于发现和开发小分子疗法,通过利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白质。 其靶向蛋白降解(TPD)平台Pegasus,使其能够发现对整个身体的致病蛋白具有活性的选择性小分子蛋白降解剂。 公司的Pegasus平台包括E3配体酶全身图谱、E3配体酶粘合剂工具箱、三元复合体模型、定量系统药理学模型和化学。 其临床阶段的项目包括IRAK4、IRAKIMiD和STAT3,它们分别针对白细胞介素-1受体/棒状受体(IL-1R/TLR)和贾努斯激酶/信号转导者和转录激活者(JAK/STAT)中的目标。 其项目重点是治疗一系列免疫炎症性疾病、血液学恶性肿瘤和实体瘤。
Industry: | Biotechnology & Medical Research (NEC) |
200 Arsenal Yards Blvd., Suite 230
2Nd Floor
WATERTOWN
MASSACHUSETTS 02472
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球485,000万多名交易者的一份子,选择利用Capital.com进行交易吧。